Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Russell

Gastroenterology Boston, MA Medical Doctor

NPI 1730592387 CMS profile 4701091

800 Washington St, Boston, MA 02111

Open in the dashboard

General payments

$11,076

585 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Russell of Boston, MA is reported in the CMS Open Payments database as having received $11,076 across 585 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,790 135
2024 General $2,591 133
2023 General $2,418 136
2022 General $2,142 119
2021 General $710 42
2020 General $196 7
2019 General $229 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Russell
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Michael Russell were reported at $2,790. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Michael Russell Gastroenterology median Middle half National median
2019 $229 $417 $126–$1,100 $163
2020 $196 $224 $74–$624 $114
2021 $710 $352 $106–$1,054 $132
2022 $2,142 $448 $129–$1,270 $149
2023 $2,418 $533 $150–$1,390 $160
2024 $2,591 $605 $160–$1,606 $164
2025 $2,790 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,246 140 payments
  2. Janssen Biotech, Inc. $1,549 66 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,099 55 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,030 59 payments
  5. Gilead Sciences, Inc. $994 51 payments
  6. Pfizer Inc. $519 29 payments
  7. Genzyme Corporation $410 19 payments
  8. Aimmune Therapeutics, Inc. $315 13 payments
  9. Regeneron Healthcare Solutions, Inc. $281 11 payments
  10. Ironwood Pharmaceuticals, Inc $227 14 payments
  11. Other $2,407 128 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,847 581 payments
  2. Education $230 4 payments
Products named General payments · program years 2019–2025
  1. STELARA $1,114 50 payments
  2. XIFAXAN $813 45 payments
  3. ENTYVIO $787 41 payments
  4. RINVOQ $738 45 payments
  5. TREMFYA $599 20 payments
  6. LINZESS $594 36 payments
  7. SKYRIZI $493 29 payments
  8. XELJANZ $468 26 payments
  9. ZENPEP $454 20 payments
  10. CREON $438 27 payments
  11. Other $5,811 313 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

488

Median for Internal Medicine: 777

Drug cost

$88,516

Median for Internal Medicine: $73,373

Branded share of claims

42.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 57 $51,819
Sucralfate Generic 43 $8,557
Trulance Plecanatide Brand 12 $6,937
Motegrity Prucalopride Succinate Brand 12 $6,785
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 101 $6,684
Dexlansoprazole Dr Dexlansoprazole Brand 14 $3,103
Pantoprazole Sodium Generic 99 $1,144
Omeprazole Generic 54 $1,096
Esomeprazole Magnesium Generic 24 $976
Dicyclomine Hcl Generic 15 $620

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$106,037

Of which drugs: $43,954

Medicare patients

221

Average age 73

Services billed

3,029

127 women, 94 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 34%
Diabetes 33%
Depression 29%
Chronic kidney disease 28%
COPD 22%
Atrial fibrillation 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Infusion, normal saline solution, 250 cc J7050 Office 11 13 $7

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $224
$224 — —
STELARA
  • Janssen Biotech, Inc. $188
$188 — —
RINVOQ
  • AbbVie, Inc. $171
$171 — —
DUPIXENT
  • GENZYME CORPORATION $106
  • Regeneron Healthcare Solutions, Inc. $58
$164 — —
SKYRIZI
  • AbbVie, Inc. $152
$152 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

585 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record